Tag: Cinryze

Over 200,000 Americans are estimated to have a rare disease known as Hereditary Angioedema (HAE), a condition caused by a deficiency or dysfunction of the C1 esterase inhibitor protein. The standard of care often involves replacing this missing protein, which is available under several different brand names for C1 inhibitor concentrate, including Berinert, Cinryze, and Haegarda.

Hereditary angioedema (HAE) affects an estimated 1 in 50,000 people globally and is caused by a deficiency or dysfunction of the C1 esterase inhibitor protein. For patients managing this rare condition, understanding **what is the generic name for C1 esterase inhibitor?** is a crucial part of treatment, as the name can vary based on the drug's origin.

Takeda Pharmaceuticals is the current manufacturer of Cinryze, but the medication has a rich history involving several pharmaceutical companies. First developed by ViroPharma, the rights to Cinryze were later acquired by Shire before eventually being integrated into Takeda's portfolio following a major corporate acquisition. This complex journey reflects the consolidation common within the modern pharmaceutical industry.